John Reed, Sanofi R&D chief (Endpoints News)
July 8, 2020 07:14 AM EDTUpdated 07:48 AM
Deals
Cell/Gene Tx

John Reed brings NK cells in­to Sanofi's CD38 ri­val­ry with J&J — and of­fers thumbs up for Kiadis' new fo­cus

Amber Tong

Sanofi doesn’t just want to be a chal­lenger to J&J’s dom­i­nant Darza­lex mul­ti­ple myelo­ma fran­chise. It’s look­ing to pi­o­neer a new ap­proach by pair­ing its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times